Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GP MDI
Glycopyrronium MDI · 1 trial · 1 indication
Evaluate the effect of 2 different GP MDI doses relative to placebo MDI as an add-on treatment to BFF MDI on lung function in 4 to less than 12 years old participants with asthma.
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence ABC | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment A, Treatment B followed by Treatment C for 3 weeks each. |
| Treatment Sequence BCA | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment B, Treatment C followed by Treatment A for 3 weeks each. |
| Treatment Sequence CAB | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment C, Treatment A followed by Treatment B for 3 weeks each. |
| Treatment Sequence ACB | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment A, Treatment C followed by Treatment B for 3 weeks each. |
| Treatment Sequence BAC | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment B, Treatment A followed by Treatment C for 3 weeks each. |
| Treatment Sequence CBA | EXPERIMENTAL | Participants will receive three treatments in sequence: Treatment C, Treatment B followed by Treatment A for 3 weeks each. |
| Name | Type | Description |
|---|---|---|
| GP MDI | COMBINATION_PRODUCT | GP MDI will be administered via oral inhalation twice daily (BID). |
| BFF MDI | COMBINATION_PRODUCT | BFF MDI will be administered via oral inhalation BID. |
| Placebo MDI | COMBINATION_PRODUCT | Placebo MDI will be adminsitered via oral inhalation BID. |
Main Inclusion Criteria: * Participants who have a documented history of physician-diagnosed asthma * Participants who have been using a stable and regular inhaled corticosteroid plus one additional asthma controller medication. * Participants must have a Childhood Asthma Control Test score ≥ 19. *...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Glycopyrronium MDI is an investigational inhaled medicine being studied for the treatment of asthma. It is being developed as an add-on therapy given together with BFF, and the current research focuses on children aged 4 to less than 12 years with asthma.
Glycopyrronium MDI targets the muscarinic acetylcholine receptors CHRM1, CHRM2, CHRM3, CHRM4, and CHRM5. It acts as an antagonist at these receptors, which are involved in airway smooth muscle contraction and bronchoconstriction, so blocking them is intended to help relax the airways and improve lung function in asthma.
Glycopyrronium MDI is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating the drug in asthma.
Glycopyrronium MDI is in Phase 2 clinical development. It is an investigational small molecule and has not been approved by the FDA for asthma; it remains under study in a randomized, double-blind, controlled trial.
Glycopyrronium MDI is being studied in the Phase 2 trial NCT07525375, which is currently recruiting. The trial has an enrollment of 69 participants and is being conducted in the United States, Argentina, Czechia, Hungary, Mexico, Poland, and Serbia.
Yes, Glycopyrronium MDI is also known as GP MDI. Both names refer to the same AstraZeneca inhaled small molecule being studied in asthma, so searches for either name point to the same investigational asset.